Releasing Q2 earnings on Monday, Hims & Hers Co-Founder and CEO Andrew Dudem said users of its personalized GLP-1 treatment plans had lost an average 10.3% of their body weight over six months, and that only 25% of them had discontinued treatment, particularly encouraging when considering discontinuation rates in certain publicly available studies reached approximately 80% percent by six months. Saying that personalized treatments allow patients to receive clear treatment instructions and educational content while also accessing tools such as water intake trackers and calorie counters, Dudem complained of pushback from traditional incumbents. During its own earnings call on Wednesday, Novo Nordisk doubled down against GLP-1 compounders that it says are still around despite the end of an FDA-granted grace period in May
Some reactions may appear later, so do not ignore new or unusual symptoms
By using glutathione regularly, the skin becomes brighter, more even, and noticeably clearer
Enriched with L-Carnitine , it helps boost metabolism, energy, and fat conversion all in a refreshing, fizzy drink
Clinical data shows that approximately 3040% of GLP-1 users experience nausea, vomiting, or constipation during the first few weeks of therapy
Clinical safety guidance suggests that semaglutide may still be safe if: Exposure was brief Temperature limits were not exceeded The medication shows no visible changes However, pharmaceutical safety standards recommend discarding biologic medications if storage conditions are uncertain, as visual inspection alone cannot confirm potency
